New Zealand headquartered regenerative medicine company Aroa Biosurgery has announced the appointment of experienced US-based executive, Brad Adams, to the new position of vice president, commercial.
Aroa CEO Brian Ward said Mr Adams brings 20 years of experience in the strategic sales and marketing of medical devices in the US.
“We are delighted to welcome Brad Adams to the senior team of Aroa. His deep experience of the US market will bring real value for us as we look to build on our clinical success with Endoform products,” said Mr Ward.
Mr Adams was most recently vice president of sales at Acell, a Maryland based regenerative medicine company, and also had more than 15 years with the Smith & Nephew and Johnson & Johnson companies.
“Brad joins us at an important moment for Aroa as we look to accelerate our U.S. growth. His background in growing and managing sales teams will help us fully leverage last year’s formation of Appulse, our 50% marketing joint venture with Hydrofera,” said Mr Ward.
“I am excited by the focus, energy and innovation Aroa has already brought to the tissue regeneration market in the United States and am looking forward to playing my part in the next wave of growth,” said Mr Adams.